TCT 2019 | PORTICO: This vs. Any Other Valve Available in the Market

Courtesy of SBHCI.

This work, presented at the TCT 2019 Scientific Sessions, showed the 30-day safety and 1-year efficacy of self-expanding prosthesis Portico compared with all valves approved by the US Food and Drug Administration (FDA) for the treatment of patients with severe aortic stenosis and high surgical risk.

Highlights TCT 2019

Between 2014 and 2019, researchers enrolled 750 patients from 69 sites and randomized them 1:1 to receive Portico or any other prosthesis. Mean patient age was 83.3 years old and the mean Society of Thoracic Surgeons (STS) score was 6.5%.

The combined safety endpoint (death, stroke, bleeding, dialysis, or vascular complications) at 30 days was 13.8% for the Portico group vs. 9.6% for all other devices, thus reaching noninferiority. The combined efficacy endpoint (all-cause death and stroke) at one year was also similar (14.9% vs. 13.4%, respectively), reaching noninferiority.

The study also included a separate cohort of 100 patients who used the new delivery system for this valve, called FlexNaV. With this new release system, Portico had less vascular complications (7%) and less permanent pacemaker implantations (14.6%).

Conclusion

The Portico valve was associated with better hemodynamic outcomes (larger areas and lower gradients), but more paravalvular leak compared with all other commercially available prostheses. The FlexNaV delivery system showed a better safety profile.

Courtesy of SBHCI.

Link to the SBHCI publication HERE

portico-1

Original Title: PORTICO: A Randomized Trial of Portico vs. Commercially Available Transcatheter Aortic Valves in Patients With Severe Aortic Stenosis.

Author of the original article: Gregory P. Fontana.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...